UniXell Biotechnology Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $7.19M

  • Investors
  • 21

UniXell Biotechnology General Information

Description

Developer of cellular therapy designed for human pluripotent stem cells. The company offers unmet medical needs, including neurodegenerative diseases and rare diseases, and it has developed multiple key technology platforms, including reprogramming technology, stem cell differentiation, SISBAR pedigree tracing technology and high-precision gene editing, thereby providing effective treatment solutions for patients afflicted with neurodegenerative disorders, rare diseases, and tumors.

Contact Information

Website
unixell.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5th Floor, Block D, Free Trade Zone
  • Number 215 Huashen Road, Pudong New Area
  • Shanghai, 200131
  • China
+86 021
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 5th Floor, Block D, Free Trade Zone
  • Number 215 Huashen Road, Pudong New Area
  • Shanghai, 200131
  • China
+86 021

UniXell Biotechnology Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

UniXell Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series A1) 11-Feb-2026 $7.19M Completed Generating Revenue
5. Early Stage VC (Series A1) 06-Nov-2025 Completed Generating Revenue
4. Early Stage VC (Series A1) 12-Jul-2024 Completed Generating Revenue
3. Early Stage VC (Series A) 31-Mar-2024 Completed Generating Revenue
2. Early Stage VC 29-Mar-2022 $31.5M $31.5M Completed Generating Revenue
1. Seed Round 25-Aug-2021 Completed Startup
To view UniXell Biotechnology’s complete valuation and funding history, request access »

UniXell Biotechnology Patents

UniXell Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026222936-A1 Method for differentiation of medial ganglionic eminence neural progenitor cells Pending 23-Apr-2025
WO-2025252180-A1 In-vitro preparation method for midbrain dopaminergic progenitor cell population Pending 05-Jun-2024
WO-2025162486-A1 An additive composition and a method for promoting differentiation into a10 precursors and/or a10 neurons Pending 31-Jan-2024
US-20240207324-A1 Method for quality control and enrichment of human dopaminergic neural precursor cells Pending 21-Apr-2021
WO-2022222974-A1 Method for quality control and enrichment of human dopaminergic neural precursor cells Inactive 21-Apr-2021 A61K35/30
To view UniXell Biotechnology’s complete patent history, request access »

UniXell Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

UniXell Biotechnology Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
Panlin Capital Venture Capital Minority
Fosun Health Capital Corporate Venture Capital Minority
Shanghai Guotou Pioneer Private Equity Fund Management Fund of Funds Minority
Shanghai Pudong Venture Capital Venture Capital Minority
Shanghai State Owned Capital Investment Government Minority
You’re viewing 5 of 21 investors. Get the full list »

UniXell Biotechnology FAQs

  • When was UniXell Biotechnology founded?

    UniXell Biotechnology was founded in 2021.

  • Where is UniXell Biotechnology headquartered?

    UniXell Biotechnology is headquartered in Shanghai, China.

  • What is the size of UniXell Biotechnology?

    UniXell Biotechnology has 40 total employees.

  • What industry is UniXell Biotechnology in?

    UniXell Biotechnology’s primary industry is Biotechnology.

  • Is UniXell Biotechnology a private or public company?

    UniXell Biotechnology is a Private company.

  • What is UniXell Biotechnology’s current revenue?

    The current revenue for UniXell Biotechnology is .

  • How much funding has UniXell Biotechnology raised over time?

    UniXell Biotechnology has raised $66.6M.

  • Who are UniXell Biotechnology’s investors?

    Panlin Capital, Fosun Health Capital, Shanghai Guotou Pioneer Private Equity Fund Management, Shanghai Pudong Venture Capital, and Shanghai State Owned Capital Investment are 5 of 21 investors who have invested in UniXell Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process